9D Home Care Pty Ltd

Cell and Gene Therapy

Tune Therapeutics | December 03, 2021

Tune Therapeutics, a biotechnology company pioneering the creation of epi-therapeutic medicines, launched today with its powerful and precise genetic tuning platform, TEMPO. This cutting-edge technology dials gene expression up or down to desired levels – with the potential to reverse pathways of cancer, genetic disease, and aging by changing cell fate and function at will. "Genetic medicine is at a tipping point. We now understand that the driving...

Medical

MindMed | January 21, 2021

MindMed, a main psychedelic medication biotech organization, reported today the beginning of the principal ever clinical preliminary estimating and assessing MDMA and LSD utilized in mix in the human body. The preliminary will be directed at the University Hospital Basel Liechti Lab, in Basel, Switzerland. If administered in combination with LSD, MDMA may expand positive abstract medication impacts, including positive state of mood and empathy, and lessen the negative feelings and...

Industrial Impact, Medical

Accesswire | March 24, 2023

Moderna, Inc. a biotechnology company pioneering messenger RNA therapeutics and vaccines, and Generation Bio Co. a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today announced that the two companies have entered into a strategic collaboration to combine Moderna's biological and technical expertise with core technologies of Generation Bio's non-viral genetic medicine platform. The collaboration aims to expand the application ...

Roivant | May 13, 2020

Roivant Sciences today announced several updates for its adaptive, randomized, double-blind, placebo-controlled, multi-center pivotal BREATHE trial evaluating the impact of intravenous (IV) treatment with gimsilumab on mortality in COVID-19 patients with lung injury or ARDS.The independent Data Monitoring Committee (DMC) for BREATHE unanimously recommended that the trial continue after a pre-specified safety assessment evaluating data from the first 10% of randomized subjects after six day...